Navigation Links
Pharmos Corporation Reports 2009 Third Quarter Results
Date:11/12/2009

ISELIN, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Pharmos Corporation (Pink Sheets: PARS) today reported financial results for the third quarter and nine-month period ended September 30, 2009.

Third Quarter Ended September 30, 2009

The Company recorded a net loss of $1.4 million, or $0.02 per share, for the third quarter 2009 compared to a net loss of $2.8 million, or $0.11 per share, in the third quarter 2008. Cash and cash equivalents totaled $1.3 million at September 30, 2009.

The decrease in net loss for the third quarter 2009 is due primarily to a 50% decrease in operating expenses to $1.4 million from $2.8 million in the third quarter 2008. The decline in operating expenses resulted from a 54% decrease in net research and development expenses to $1.1 million compared to $2.3 million in the third quarter 2008. Also general and administrative expenses decreased 22% in the third quarter 2009.

Research & development expenses decreased by $1,251,622 or 54% from $2,298,882 in 2008 to $1,047,260 in 2009, related to the Company's primary focus of cash resources on the Dextofisopam Phase 2b trial and the downsizing and curtailment of general research and development programs. The decline reflects decreases in virtually every research and development expense category. The primary reductions include a $175,000 reduction in payroll, a $109,000 reduction in consultant and professional fees, an $858,000 reduction in clinical studies and $110,000 reduction in various other areas. The decrease in these costs, reflect the closing of the Rehovot facility effective October 31, 2008 and the fact that the Dextofisopam trial is complete.

In the quarter ended September 30, 2009, the Company completed a Phase 2b trial of its lead compound, Dextofisopam, in female IBS patients. The Phase 2b trial was fully enrolled on April 9, 2009 at 324 patients. Costs of $971,000 were incurred during the quarter in connect
'/>"/>

SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmos Issues Business Update on Dextofisopam Trial and Financing
2. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
3. MedCath Corporation Reports Fourth Quarter Earnings
4. Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA
5. Dr. John Mills and Joseph Gentile Join Board of Directors of ChanTest Corporation
6. Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast
7. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
8. China National Medicines Corporation Issues Milestone Purchase Order for 12,000 STA Systems
9. China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou
10. MedCath Corporation to Hold Conference Call on Fourth Quarter Results
11. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014  ConvaTec, a privately-held medical products and ... has been appointed chief financial officer of the company, ... previously executive vice president and chief financial officer of ... company.  Mr. Clerkin was part of a senior team ... in its sale to Perrigo, a pharmaceutical manufacturer, in ...
(Date:7/22/2014)... LOUIS , July 22, 2014  According to ... time their children spend on digital devices. An AOA ... ages of 10 and 17 estimate they use an ... However, a separate AOA survey of parents revealed that ... an electronic device for that same amount of time. ...
(Date:7/22/2014)... LOS ANGELES , July 22, 2014  NeuroSigma, ... sciences company focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, today announced that enrollment ... external trigeminal nerve stimulation (eTNS) as adjunctive therapy for ... trial is being conducted at the Olive View-UCLA Medical ...
Breaking Medicine Technology:ConvaTec Names Nigel Clerkin Chief Financial Officer 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5
(Date:7/22/2014)... Antonio, TX (PRWEB) July 22, 2014 Dr. ... Designed with existing patients and new visitors in mind, one ... clean, modern and visual layout that makes navigation very easy. ... make the experience of going to the dentist affordable, convenient ... , One helpful new feature is an appointment scheduling system ...
(Date:7/22/2014)... Indianapolis, IN (PRWEB) July 22, 2014 ... benefits advisory organization, announces that Les McPhearson, an insurance ... serve as CEO effective immediately and be based in ... Calise, said, "I am delighted that Les chose to ... is perfectly qualified to address the many challenges facing ...
(Date:7/22/2014)... HealthDay Reporter TUESDAY, July 22, 2014 (HealthDay ... in the veins of the legs appear no different in ... risk of bleeding and average hospitalization bills that are three ... finds. The standard treatment for these clots -- known ... compression stockings. The other, more expensive treatment delivers medication directly ...
(Date:7/22/2014)... 22, 2014) The American Society of Hematology (ASH) ... School of Medicine, and Robert P. Hebbel, MD, of ... Ernest Beutler Lecture and Prize for their significant research ... The Ernest Beutler Lecture, named for the late Ernest ... for more than 50 years, is a two-part lectureship ...
(Date:7/22/2014)... research at the University of Utah,s John A. Moran ... of Eye Research (ISER) as the recipient of the ... Award in Retina Research., The award recognizes lifetime achievement ... contribution to the understanding of vitreoretinal diseases or disorders. ... ISER Biennial Meeting in San Francisco, where Marc will ...
Breaking Medicine News(10 mins):Health News:Dr. Dental Reveals Exciting New Website 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2
... Rostock Center for the study of Demographic Change, have ... be //soon reduced, if the trend of low participation ... ,The Rostock Center is a research institution, ... for Demographic Research and the University of Rostock. The ...
... lead in a global ,program to catalogue human mutations in ... access//. ,For a sample of the expected ... professor at the division of human genetics at the University ... a family who suffered from a heredity eye disease, which ...
... A Geography professor of Kansas State University, Doug Goodin, ... of land use and land cover //changes on human ... uses, combines remote sensing with other types of data, ... Along with other scientists he recently discussed this subject ...
... Chicago – The extended use of anabolic androgenic steroid ... // Gingival enlargement occurs when the tissues ... is a fertile environment for bacteria to grow, which ... that AAS abusers had statistically significant levels of gingival ...
... of misconception about Cannabis and its effects. It is widely ... // Such misrepresentations of the drug have resulted in making ... Karolinska Institute in Sweden have unearthed the harmful effects of ... ingredient in cannabis. It was found that the brain of ...
... medical specialist, NHS can be freed from its’ problems, ... before they are implemented. // It is amply clear ... make matters worse for the deprived and under privileged ... led to low morale among Doctors and NHS staff. ...
Cached Medicine News:Health News:Demographic Change Demand a New Life-Course for Aging Society 2Health News:Developing Countries Undertake Cataloguing of Human Mutations 2Health News:Developing Countries Undertake Cataloguing of Human Mutations 3Health News:Satellite Imagery to monitor the Social Impact Of Geographical Changes 2Health News:A connection between gingival enlargement and steroid abuse 2
Landolt hypophysectomie instrument, spoon, bayonet-shaped, flexible....
Hardy pituitary spoon, bayonet, malleable....
... Sundt AVM Micro ... construction, non-magnetic, MRI compatible, ... coiled, high minimum closing ... of small perforating vessels ...
... Cougar is an Anterior Spinal Implant system. ... approximating that of cortical bone. The result ... requirements of anterior column support, while optimizing ... sharing design. Incorporates an anatomic design with ...
Medicine Products: